In brief
Karl Deisseroth, Peter Hegemann and Georg Nagel received the 2026 Nobel Prize in Physiology or Medicine for inventing optogenetics, a technique that uses light to control neurons. By illuminating specific brain cells, they mapped circuits involved in memory, feelings and behavior, opening new avenues for understanding neurological disorders. Their work also inspires therapies aimed at restoring vision in patients with visual impairment. The laureates’ research marks a watershed moment in neuroscience, bridging basic science and clinical applications. Their discovery has set the stage for future interventions targeting brain circuits in mental health and sensory deficits.
US psychiatrist and neurologist Karl Deisseroth, along with German colleagues Peter Hegemann and Georg Nagel, were awarded the 2026 Nobel Prize in Physiology or Medicine for pioneering optogenetics, a groundbreaking method that uses light to precisely control neural activity.
Optogenetics allows scientists to illuminate individual neurons and observe the behavioral outcomes, revealing how specific circuits give rise to memory, emotions and actions. The trio’s work has illuminated the pathways behind what scientists once thought of as “black boxes” in the brain, setting a new standard for neuroscientific exploration.
The Nobel Committee highlighted the research as a foundation for a new era, noting its implications for understanding and treating neurological and psychiatric disorders such as depression, anxiety and Parkinson’s disease.
Beyond basic science, clinicians are already exploring optogenetics to restore sight in patients with visual impairment, aiming to re‑wire damaged retinal pathways through light‑activated proteins.
As the field moves forward, the laureates’ inventions promise to translate the precise control of brain circuits into therapies for a range of mental and sensory conditions, heralding a promising future for neuro‑medicine.
